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Summary 
We investigated changes in the plasma proteome of children with sickle cell anaemia 
(SCA) associated with hydroxycarbamide (HC) use, to further characterize the actions 
of HC. 
51 children with SCA consented to take part in this study. 18 were taking HC at a 
median dose of 22mg/kg, and 33 were not on HC. Plasma was analyzed using an 
unbiased proteomic approach and a panel of 92 neurological biomarkers. HC was 
associated with increased haemoglobin (Hb) (89.8g/l vs 81.4g/l, P=0.007) and HbF 
(6.7 vs 15.3%, P<0.001). 17 proteins were decreased on HC compared to controls by 
a factor of <0.77, and six proteins showed >1.3 increased concentration. HC use was 
associated with reduced haemolysis (lower    globin chains, haptoglobin related 
protein, complement C9; higher hemopexin), reduced inflammation (lower -1-acid 
glycoprotein, CD5 antigen-like protein, ceruloplasmin, factor XII, immunoglobulins, 
cysteine-rich secretory protein 3, vitamin D-binding protein) and decreased 
activation of coagulation (lower factor XII, carboxypeptidase B2, platelet basic 
protein). There was a significant correlation between the increase in HbF% on HC 
and hemopexin levels (R=0.603, P=0.023). This study demonstrated three ways in 
which HC may be beneficial in SCA, and identified novel proteins, which may be 
useful to monitor therapeutic response.  
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Introduction 
The most prevalent and severe type of sickle cell disease is caused by homozygosity 
for the sickle mutation (HBB; c.20A>T, p.Glu7Val), and referred to as sickle cell 
anaemia (SCA). It is one of the commonest severe inherited disorders in the world, 
and associated with unpredictable acute complications, progressive organ damage 
and shortened life expectancy(Brousse, et al 2014). Although outcomes have 
improved significantly in high-income countries over the last 40 years, there are still 
very few treatments available, with hydroxycarbamide (HC) continuing to be the only 
drug which has convincingly been shown to modify the natural history of the 
condition and potentially prevent organ damage(McGann and Ware 2015). 
 
Randomized controlled trials have shown that HC reduces the frequency of acute 
pain and acute chest syndrome(Charache, et al 1995, Wang, et al 2011), reduces the 
need for blood transfusion(Charache, et al 1995), reduces the risk of infection and 
malaria in some settings(Tshilolo, et al 2018), and is effective as part of the 
management of abnormal transcranial Doppler (TCD) velocities(Ware, et al 2016). 
Uncontrolled studies also suggest that HC increases oxygen saturations(Singh, et al 
2008), decreases albuminuria(Tehseen, et al 2017) and may increase life expectancy 
in adults(Steinberg, et al 2003). In the USA and UK it is recommended that HC is 
offered to all children with SCA (Qureshi, et al 2018, Yawn, et al 2014), and 
approximately 80% children take it in some large centres in the USA; in Europe 
practice varies widely, but HC is offered to most symptomatic children. 
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The main mechanism of action of HC is to increase haemoglobin F (HbF) production, 
which decreases the rate of HbS polymerization, with subsequent improvement in 
many downstream pathologies, including reductions in vaso-occlusion, 
inflammation, anaemia and haemolysis(Ware 2010). HC has some other actions 
beyond the  globin locus, including reducing white cell numbers, decreasing 
expression of adhesion molecules on the vascular endothelium and possibly 
improving nitric oxide metabolism(Rees 2011), although it is unclear how much 
these contribute to its therapeutic actions. In a mouse model of sickle cell disease in 
which HC caused no increase in HbF levels, there was no evidence of improvement in 
clinical or laboratory parameters(Lebensburger, et al 2010). 
 
Another important unanswered question involves variability in the therapeutic 
response to HC. It is unclear why some patients appear not to respond as well as 
others. Some of this may be related to drug adherence, although all studies show a 
variable response. In the HUSTLE study the HbF level varied from 16.2 – 27.8% after 
one year in patients achieving the maximum tolerated dose(Estepp, et al 2017); 
some of this variability is related to baseline HbF levels, although analysis of data 
from the HUG-KIDS study showed that this explained only about 18% of the HbF 
response(Ware, et al 2002). 
 
Previous studies have measured the effects of HC on selected biomarkers, such as 
indicators of inflammation (Penkert, et al 2018) or vasculopathy (Lapoumeroulie, et 
al 2005), but we have adopted an unbiased proteomic approach to identify changes 
in plasma protein levels associated with HC use. We hypothesized that there would 
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be significant differences in the plasma proteome between children with SCD taking 
and not taking HC, and that these differences would shed light on the mechanism of 
action of HC and may identify novel biomarkers associated with response to HC. 
 
Methods 
Patients and setting  
The data were collected as part of a study of silent cerebral infarcts (SCIs), funded by 
the Stroke Association (Grant TSA 2012/06)(Tewari, et al 2018). The study was 
approved by the UK National Research Ethics Committee (reference 13/LO/0709) 
and all patients/parents gave written consent. Children with SCA were recruited 
from clinics at King’s College Hospital and the Evelina Children’s Hospital. The aim 
was to recruit 50 patients, with approximately equal numbers of those with SCIs and 
controls with normal brain MRIs. Children already known to have SCIs from previous 
MRI scans were selectively recruited and eligible patients without previous MRIs 
were recruited sequentially as they attended clinic. Children taking HC were 
recruited to both arms and had been on a stable dose of HC for at least 6 months. 
Inclusion criteria were: sickle cell anaemia (HbSS), age 8-18 years old, normal or 
conditional TCD velocities (<200cm/s), able to tolerate MRI scan without sedation. 
Exclusion criteria were: history of overt stroke, blood transfusion in last 4 months, 
serious co-existing disorder, acute complications requiring hospital attendance in 
last 3 months. 
 
 
Routine Clinical and Laboratory data 
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Routine steady-state laboratory analyses were recorded, including haemoglobin, 
haemoglobin F levels, white cell count, reticulocyte count, renal function, hepatic 
function, lactate dehydrogenase, G6PD status, and C-reactive protein. 
 
Proteomic Analysis 
Blood samples were collected on all children at the time of consent. A data-driven 
proteomics approach was used to discover protein changes in the plasma associated 
with HC use. We used an established a workflow combining isobaric Tandem Mass 
Tags (TMT) reagents with 1D gel separation, followed by high sensitivity rapid 
throughput MS and MS/MS analysis, referred to as TMT-GelC/MS/MS. TMT®s 
(Proteome Sciences plc) are a set of isobaric mass tags for labeling proteins and 
peptides at amine functions and subsequent mixing of up to six different protein 
samples. During MS/MS, each set of tags gives rise to different reporter ions with 
specific molecular masses thus allowing them to share the same chemical structure 
but have different molecular weights dependent on the different number of heavy 
isotopes contained. Peptides labelled with different TMTs show identical 
chromatographic retention times as well as identical ionization and fragmentation 
behaviour of tags and tagged species. 
 
The TMT-GeLC-MS/MS method involved TMT labelling of samples, pooling and then 
single 1D electrophoresis. Fractionation by gel sectioning (~10 sections) was 
followed by in-gel digestion prior to LC/MS/MS. This method of labelling proteins, 
rather than labelling digested peptides, reduced variation in reporter intensities 
from bias introduced by loading artefacts and extraction efficiency. The use of the 
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initial 1D gel allowed separate analysis of gel regions containing more protein from 
those containing fewer proteins leading to more even coverage of the proteome.  
Protein discovery study was performed in a reference-controlled manner using the 
TMT-GeLC/MS/MS workflow and this approach generated considerable coverage 
of the plasma proteome(Engmann, et al 2010). 
  
Mass spectral data were acquired using an Orbitrap Velos mass spectrometer 
(Thermo Scientific). Compilation and validation of the peptide and protein 
assignments were carried out using Proteome Discoverer v1.3 (Thermo) and Scaffold 
v2.6 (Proteome Software Inc) mass spectrometry software. Proteins were quantified 
based on the intensities of the reporter ions released from the TMT tags during 
MS/MS of peptides. The use of the TMT6plex reagents enabled the simultaneous 
analysis of a five samples alongside an overall study reference comprising of a pool 
of all subjects. The proteomics study comprised 10 separate TMT6plex experiments, 
each with 5 samples and a reference channel for normalization purposes. 10 gel 
sections from each TMT set were analysed by LC/MS/MS. 
 
Data were exported for each TMT set into an Excel file, and duplicate peptides were 
removed. The data were filtered so that only peptides identified in all 10 sample 
channels were analysed further. The data were normalized and merged against the 
peptide sequence using R software. The merged data were further filtered such that 
only peptides present in all patient samples were studied. Relative amounts of each 
peptide were compared between the SCI and control groups, and P values calculated 
for 1.3 fold differences. 
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Targeted plasma analysis for biomarkers of neurological disease 
Plasma samples were also analysed for 92 protein biomarkers known to be 
implicated in neurological disease, using a multiplexed proximity extension 
assay(Assarsson, et al 2014). Plasma samples, anticoagulated with EDTA, were frozen 
at -80oC within 6 hours of venesection, and transported as one batch to Olink 
Proteomics in Sweden (www.olink.com/proseek-multiplex) on dry ice for analysis 
using their Proseek Multiplex Neurology I panel (see Supplementary Materials for 
full list of biomarkers). 
 
Data Analysis 
Means were compared with adjustments for multiple comparisons when 
appropriate. Statistical analyses were performed in the Proteomics Laboratory and 
medical statistics department of Public Health Sciences at King’s College London. 
 
 
Results 
Basic laboratory measurements 
51 patients (22 female) were included in the study, and 18 of these were taking HC. 
The median dose of HC was 22 (range 18 – 24) mg/kg/day. 19 had SCIs and 32 
normal brain MRI. There was no significant difference in HC use between SCI and 
control groups: 7/19 children with SCIs were taking HC compared to 11/32 without 
SCIs (Chi square, P=0.859)(Tewari, et al 2018). G6PD status was known for 45 
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patients and there was no association with HC use; G6PD deficiency was present in 
2/16 on HC and 3/29 controls (Chi square, P=0.826). Steady-state laboratory data are 
given in Table 1. These measurements showed the expected patterns, and in 
particular the significant increase in HbF levels associated with HC use (6.7 vs 15.3%, 
P<0.001). 
 
Plasma proteomic and targeted analysis 
4662 different peptides were identified across all patients. Of these 1312, from 346 
different proteins, were present in all 51 patients and were used for ongoing 
analysis. Peptides from the fibrinogen gamma chain and Complement C3 showed 
inconsistent patterns, with some peptides elevated on HC and others decreased, and 
were not considered further. 
 
On unbiased proteomic analysis, six proteins were present at significantly increased 
concentrations in children on HC (Table 2), and 17 were significantly lower with HC 
(Table 3), including alpha, beta and delta globin chains.  
 
Targeted analysis of the samples for biomarkers of neurological disease showed 
significant differences in 18 proteins between those taking and not taking HC, but 
only three of these remained significant after correction for multiple comparisons 
(Table 4). 
 
Correlation between changes in HbF levels in HC and plasma proteins 
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Changes in HbF% on HC were calculated by subtracting the HbF% immediately 
before starting HC from the HbF% on the day when the sample for proteomic 
analysis was taken. In 7 patients reliable steady-state HbF levels were unavailable 
pre-HC, because of young patient age or blood transfusions. Correlation coefficients 
were calculated between these changes in HbF% and concentrations of proteins 
significantly changed in those on hydroxyurea. The change in HbF% correlated 
significantly with plasma concentrations of hemopexin (R=0.603, P=0.023), 
ceruloplasmin (R=-0.589, P=0.023), immunoglobulin J chain (R=0.537, P=0.048) and 
platelet basic protein (R=-0.581, P=0.029) (Table 5). For patients taking HC, 
correlation coefficients were also calculated between HbF% on the day of consent 
and protein levels: HbF% correlated significantly with hemopexin (R=0.503, P=0.013), 
and also   and  globin levels, all of which suggest that greater increases in HbF% 
on hydroxyurea are associated with decreased rates of intravascular haemolysis. No 
such relationship was seen on analysis of the pre-HC HbF% (Table 5). 
 
Discussion 
Routine laboratory measurements showed the expected changes, with HC 
associated with increases in HbF, haemoglobin and MCV, and reductions in 
reticulocyte and neutrophil counts. All these changes may be of some therapeutic 
value, as well as being indirect indicators of reduced HbS polymerization. 
 
Peptides from six proteins were found at >1.3 fold higher concentrations in children 
taking HC. It is difficult to know the significance of increased levels of -1B-
glycoprotein and -2-macroglobulin: -1B-glycoprotein is an immunoglobulin-like 
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protein of unknown function and -2-macroglobulin is a multi-functional proteinase 
inhibitor, which has been found at increased concentrations in patients with 
SCA(Makis, et al 2000). Apolipoprotein C-III is central to triglyceride 
metabolism(Norata, et al 2015) but again the biological significance of elevated 
levels in patients with SCA on HC is unclear. In SCA, plasma fibronectin has been 
implicated in the adherence of reticulocytes to monocytes(Brittain, et al 2008), and 
elevated levels associated with HC could potentially be detrimental, although it 
could also reflect reduced consumption associated with lower reticulocyte and 
monocyte counts. Similarly, plasma vitronectin levels are increased in children taking 
HC, and this glycopeptide is implicated in intercellular adhesion and control of the 
extracellular environment(Leavesley, et al 2013). These findings require further 
investigation. Perhaps most interestingly, increased hemopexin concentrations were 
also found in association with HC; hemopexin is the scavenger molecular for free 
haem, and levels have previously been shown to be depleted in SCA(Santiago, et al 
2018), with some evidence of therapeutic benefit from hemopexin infusion(Belcher, 
et al 2018). Our finding of increased hemopexin levels associated with HC has not 
been shown before, and is in keeping with decreased rates of haemolysis, and 
suggests another probable beneficial action of HC in SCA. 
 
Proteomic analysis identified peptides from 17 different proteins which were found 
at >1.3 fold higher concentrations in controls. As for hemopexin, some of these are 
attributable directly to the reduced rate of red cell destruction associated with 
higher HbF levels:    globin chains and haptoglobin-related protein; the latter 
binds haemoglobin but is not removed by CD163, and is thought to be included in 
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measurements of free plasma haemoglobin(Nielsen, et al 2006). Complement C9 has 
been shown to bind to denser sickle cells and increase susceptibility to lysis, and 
lower levels with HC may be either a cause or effect of reduced haemolysis(Test and 
Woolworth 1994).  The reduced levels of all of these are in keeping with lower levels 
of plasma haemoglobin, which is thought to be a significant causal factor in the 
endothelial dysfunction which is characteristic of SCA(Reiter, et al 2002). 
 
A second group of proteins found at lower levels in those on HC were markers of 
inflammation, suggesting that HC is associated with decreased inflammation in SCA: 
-1-acid glycoprotein (also called orosomucoid) for which high urinary levels are 
associated with kidney disease in SCA(Jerebtsova, et al 2018), CD5 antigen-like 
protein(Prentice, et al 2010), ceruloplasmin, factor XII, immunoglobulins ( chain C 
region, and J chain), vitamin D-binding protein(Chishimba, et al 2010) and cysteine-
rich secretory protein 3, which is released on neutrophil degranulation(Udby, et al 
2002). 
 
A third group of proteins present at lower levels in those on HC involved 
procoagulant factors: Factor XII; carboxypeptidase B2, which attenuates 
fibrinolysis(Leenaerts, et al 2018) and platelet basic protein, which is released by 
activated platelets(El-Gedaily, et al 2004). It is harder to interpret the decreased 
levels of serotransferrin in those taking HC. 
 
We assessed the potential clinical significance of the plasma protein differences by 
calculating correlation coefficients between these plasma proteins and changes in 
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HbF% associated with HC use. Markers of intravascular haemolysis (hemopexin, 
globin chains) correlated positively with HbF% at the time of blood sampling, and 
hemopexin also correlated also with the increase in HbF% associated with HC use, 
confirming that higher HbF levels are associated with reduced intravascular 
haemolysis. Interestingly, there was no correlation between inflammatory markers 
and HbF% on HC, although there was a negative correlation between the increase in 
HbF% with HC  and two inflammatory markers (ceruloplasmin and platelet basic 
protein). This possibly suggests that children with less inflammation respond with a 
bigger increase in HbF% on HC, although this needs to be studied in larger, 
prospective studies. 
 
Three of the targeted panel of neurological biomarkers were significantly reduced in 
those taking HC. Plexin-B3 is expressed in brain tissue and involved in axon 
guidance(Rujescu, et al 2007), and possibly lower levels suggest reduced neuronal 
damage associated with HC use. Reduced interleukin 12  and leukocyte-associated 
immunoglobuin-like receptor-2(Lebbink, et al 2008) levels both suggested reduced 
inflammation associated with HC, in keeping with the findings of the unbiased 
proteomic analysis. 
 
Our study is cross-sectional rather than longitudinal, raising the possibility that the 
differences between the two groups could be related to pre-existing clinical 
differences rather than as a consequence of HC use. This is unlikely in that the 
changes in the HC group (higher haemoglobin, less inflammation, reduced 
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coagulability) indicate less severe disease, whereas in general more severely affected 
children are offered HC. 
 
Using an unbiased proteomic approach, our study identifies plasma proteins that are 
modulated by HC use and are associated with pathways involved in decreased rates 
of haemolysis (6 proteins), reduced inflammation (9 proteins), and reduced 
hypercoagulability (3 proteins). Such differences are largely explicable as 
downstream changes associated with higher HbF levels and slower HbS 
polymerization(Lebensburger, et al 2010), resulting in less red cell damage and vaso-
occlusion, and are in keeping with the previously documented therapeutic actions of 
HC(Ware 2010). Although these results need confirming in prospective longitudinal 
studies, some or all of the proteins identified in our study may be useful to monitor 
patients treated with HC, potentially to optimize and individualize the dose used.   
 
 
 
 
Acknowledgements 
 
We thank James Barrett of the Division of Health & Social Care Research, King's 
College London for help with the statistical analysis, and all the children and families 
who agreed to take part in this study. This study was supported by a grant from The 
Stroke Association, UK. 
JB analysed the data and contributed to writing the manuscript. ST recruited 
patients, prepared samples and contributed to writing the manuscript. SM helped 
 15 
analyse data and contributed to writing the manuscript. FK helped design the study 
and contributed to writing the manuscript. BI recruited patients to the study and 
contributed to writing the manuscript. GR performed proteomic studies, analysed 
the data and contributed to writing the manuscript. MW helped design the study, 
supervised proteomic studies, helped analyse the data and contributed to writing 
the manuscript. DR designed the study, analysed the data and wrote the manuscript. 
 
  
 16 
Assarsson, E., Lundberg, M., Holmquist, G., Bjorkesten, J., Thorsen, S.B., Ekman, D., 
Eriksson, A., Rennel Dickens, E., Ohlsson, S., Edfeldt, G., Andersson, A.C., 
Lindstedt, P., Stenvang, J., Gullberg, M. & Fredriksson, S. (2014) Homogenous 
96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent 
scalability. PLoS One, 9, e95192. 
Belcher, J.D., Chen, C., Nguyen, J., Abdulla, F., Zhang, P., Nguyen, H., Nguyen, P., 
Killeen, T., Miescher, S.M., Brinkman, N., Nath, K.A., Steer, C.J. & Vercellotti, 
G.M. (2018) Haptoglobin and hemopexin inhibit vaso-occlusion and 
inflammation in murine sickle cell disease: Role of heme oxygenase-1 
induction. PLoS One, 13, e0196455. 
Brittain, J.E., Knoll, C.M., Ataga, K.I., Orringer, E.P. & Parise, L.V. (2008) Fibronectin 
bridges monocytes and reticulocytes via integrin alpha4beta1. Br J Haematol, 
141, 872-881. 
Brousse, V., Makani, J. & Rees, D.C. (2014) Management of sickle cell disease in the 
community. BMJ, 348, g1765. 
Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., 
McMahon, R.P. & Bonds, D.R. (1995) Effect of hydroxyurea on the frequency 
of painful crises in sickle cell anemia. Investigators of the Multicenter Study 
of Hydroxyurea in Sickle Cell Anemia. N Engl J Med, 332, 1317-1322. 
Chishimba, L., Thickett, D.R., Stockley, R.A. & Wood, A.M. (2010) The vitamin D axis 
in the lung: a key role for vitamin D-binding protein. Thorax, 65, 456-462. 
El-Gedaily, A., Schoedon, G., Schneemann, M. & Schaffner, A. (2004) Constitutive 
and regulated expression of platelet basic protein in human monocytes. J 
Leukoc Biol, 75, 495-503. 
Engmann, O., Campbell, J., Ward, M., Giese, K.P. & Thompson, A.J. (2010) 
Comparison of a protein-level and peptide-level labeling strategy for 
quantitative proteomics of synaptosomes using isobaric tags. J Proteome Res, 
9, 2725-2733. 
Estepp, J.H., Smeltzer, M.P., Kang, G., Li, C., Wang, W.C., Abrams, C., Aygun, B., 
Ware, R.E., Nottage, K. & Hankins, J.S. (2017) A clinically meaningful fetal 
hemoglobin threshold for children with sickle cell anemia during hydroxyurea 
therapy. Am J Hematol, 92, 1333-1339. 
Jerebtsova, M., Saraf, S.L., Soni, S., Afangbedji, N., Lin, X., Raslan, R., Gordeuk, V.R. & 
Nekhai, S. (2018) Urinary orosomucoid is associated with progressive chronic 
kidney disease stage in patients with sickle cell anemia. Am J Hematol, 93, 
E107-E109. 
Lapoumeroulie, C., Benkerrou, M., Odievre, M.H., Ducrocq, R., Brun, M. & Elion, J. 
(2005) Decreased plasma endothelin-1 levels in children with sickle cell 
disease treated with hydroxyurea. Haematologica, 90, 401-403. 
Leavesley, D.I., Kashyap, A.S., Croll, T., Sivaramakrishnan, M., Shokoohmand, A., 
Hollier, B.G. & Upton, Z. (2013) Vitronectin--master controller or 
micromanager? IUBMB Life, 65, 807-818. 
Lebbink, R.J., van den Berg, M.C., de Ruiter, T., Raynal, N., van Roon, J.A., Lenting, 
P.J., Jin, B. & Meyaard, L. (2008) The soluble leukocyte-associated Ig-like 
receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune 
interaction. J Immunol, 180, 1662-1669. 
 17 
Lebensburger, J.D., Pestina, T.I., Ware, R.E., Boyd, K.L. & Persons, D.A. (2010) 
Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell 
mouse model. Haematologica, 95, 1599-1603. 
Leenaerts, D., Loyau, S., Mertens, J.C., Boisseau, W., Michel, J.B., Lambeir, A.M., 
Jandrot-Perrus, M. & Hendriks, D. (2018) Carboxypeptidase U (CPU, 
carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) 
inhibition stimulates the fibrinolytic rate in different in vitro models. J 
Thromb Haemost, 16, 2057-2069. 
Makis, A.C., Hatzimichael, E.C., Mavridis, A. & Bourantas, K.L. (2000) Alpha-2-
macroglobulin and interleukin-6 levels in steady-state sickle cell disease 
patients. Acta Haematol, 104, 164-168. 
McGann, P.T. & Ware, R.E. (2015) Hydroxyurea therapy for sickle cell anemia. Expert 
Opin Drug Saf, 14, 1749-1758. 
Nielsen, M.J., Petersen, S.V., Jacobsen, C., Oxvig, C., Rees, D., Moller, H.J. & 
Moestrup, S.K. (2006) Haptoglobin-related protein is a high-affinity 
hemoglobin-binding plasma protein. Blood, 108, 2846-2849. 
Norata, G.D., Tsimikas, S., Pirillo, A. & Catapano, A.L. (2015) Apolipoprotein C-III: 
From Pathophysiology to Pharmacology. Trends Pharmacol Sci, 36, 675-687. 
Penkert, R.R., Hurwitz, J.L., Thomas, P., Rosch, J., Dowdy, J., Sun, Y., Tang, L. & 
Hankins, J.S. (2018) Inflammatory molecule reduction with hydroxyurea 
therapy in children with sickle cell anemia. Haematologica, 103, e50-e54. 
Prentice, R.L., Paczesny, S., Aragaki, A., Amon, L.M., Chen, L., Pitteri, S.J., McIntosh, 
M., Wang, P., Buson Busald, T., Hsia, J., Jackson, R.D., Rossouw, J.E., Manson, 
J.E., Johnson, K., Eaton, C. & Hanash, S.M. (2010) Novel proteins associated 
with risk for coronary heart disease or stroke among postmenopausal women 
identified by in-depth plasma proteome profiling. Genome Med, 2, 48. 
Qureshi, A., Kaya, B., Pancham, S., Keenan, R., Anderson, J., Akanni, M., Howard, J. & 
British Society for, H. (2018) Guidelines for the use of hydroxycarbamide in 
children and adults with sickle cell disease: A British Society for Haematology 
Guideline. Br J Haematol, 181, 460-475. 
Rees, D.C. (2011) The rationale for using hydroxycarbamide in the treatment of sickle 
cell disease. Haematologica, 96, 488-491. 
Reiter, C.D., Wang, X., Tanus-Santos, J.E., Hogg, N., Cannon, R.O., 3rd, Schechter, 
A.N. & Gladwin, M.T. (2002) Cell-free hemoglobin limits nitric oxide 
bioavailability in sickle-cell disease. Nat Med, 8, 1383-1389. 
Rujescu, D., Meisenzahl, E.M., Krejcova, S., Giegling, I., Zetzsche, T., Reiser, M., Born, 
C.M., Moller, H.J., Veske, A., Gal, A. & Finckh, U. (2007) Plexin B3 is 
genetically associated with verbal performance and white matter volume in 
human brain. Mol Psychiatry, 12, 190-194, 115. 
Santiago, R.P., Guarda, C.C., Figueiredo, C.V.B., Fiuza, L.M., Aleluia, M.M., Adanho, 
C.S.A., Carvalho, M.O.S., Pitanga, T.N., Zanette, D.L., Lyra, I.M., Nascimento, 
V.M.L., Vercellotti, G.M., Belcher, J.D. & Goncalves, M.S. (2018) Serum 
haptoglobin and hemopexin levels are depleted in pediatric sickle cell disease 
patients. Blood Cells Mol Dis, 72, 34-36. 
Singh, S.A., Koumbourlis, A.C. & Aygun, B. (2008) Resolution of chronic hypoxemia in 
pediatric sickle cell patients after treatment with hydroxyurea. Pediatr Blood 
Cancer, 50, 1258-1260. 
 18 
Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, 
E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., 
Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., 
Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., 
Bonds, D. & Terrin, M. (2003) Effect of hydroxyurea on mortality and 
morbidity in adult sickle cell anemia: risks and benefits up to 9 years of 
treatment. JAMA, 289, 1645-1651. 
Tehseen, S., Joiner, C.H., Lane, P.A. & Yee, M.E. (2017) Changes in urine albumin to 
creatinine ratio with the initiation of hydroxyurea therapy among children 
and adolescents with sickle cell disease. Pediatr Blood Cancer, 64. 
Test, S.T. & Woolworth, V.S. (1994) Defective regulation of complement by the sickle 
erythrocyte: evidence for a defect in control of membrane attack complex 
formation. Blood, 83, 842-852. 
Tewari, S., Renney, G., Brewin, J., Gardner, K., Kirkham, F., Inusa, B., Barrett, J.E., 
Menzel, S., Thein, S.L., Ward, M. & Rees, D.C. (2018) Proteomic analysis of 
plasma from children with sickle cell anemia and silent cerebral infarction. 
Haematologica, 103, 1136-1142. 
Tshilolo, L., Tomlinson, G., Williams, T.N., Santos, B., Olupot-Olupot, P., Lane, A., 
Aygun, B., Stuber, M.A., Latham, T.S., McGann, P.T. & Ware, R. (2018) 
Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. N Engl 
J Med. 
Udby, L., Calafat, J., Sorensen, O.E., Borregaard, N. & Kjeldsen, L. (2002) 
Identification of human cysteine-rich secretory protein 3 (CRISP-3) as a matrix 
protein in a subset of peroxidase-negative granules of neutrophils and in the 
granules of eosinophils. J Leukoc Biol, 72, 462-469. 
Wang, W.C., Ware, R.E., Miller, S.T., Iyer, R.V., Casella, J.F., Minniti, C.P., Rana, S., 
Thornburg, C.D., Rogers, Z.R., Kalpatthi, R.V., Barredo, J.C., Brown, R.C., 
Sarnaik, S.A., Howard, T.H., Wynn, L.W., Kutlar, A., Armstrong, F.D., Files, 
B.A., Goldsmith, J.C., Waclawiw, M.A., Huang, X., Thompson, B.W. & 
investigators, B.H. (2011) Hydroxycarbamide in very young children with 
sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). 
Lancet, 377, 1663-1672. 
Ware, R.E. (2010) How I use hydroxyurea to treat young patients with sickle cell 
anemia. Blood, 115, 5300-5311. 
Ware, R.E., Davis, B.R., Schultz, W.H., Brown, R.C., Aygun, B., Sarnaik, S., Odame, I., 
Fuh, B., George, A., Owen, W., Luchtman-Jones, L., Rogers, Z.R., Hilliard, L., 
Gauger, C., Piccone, C., Lee, M.T., Kwiatkowski, J.L., Jackson, S., Miller, S.T., 
Roberts, C., Heeney, M.M., Kalfa, T.A., Nelson, S., Imran, H., Nottage, K., 
Alvarez, O., Rhodes, M., Thompson, A.A., Rothman, J.A., Helton, K.J., Roberts, 
D., Coleman, J., Bonner, M.J., Kutlar, A., Patel, N., Wood, J., Piller, L., Wei, P., 
Luden, J., Mortier, N.A., Stuber, S.E., Luban, N.L., Cohen, A.R., Pressel, S. & 
Adams, R.J. (2016) Hydroxycarbamide versus chronic transfusion for 
maintenance of transcranial doppler flow velocities in children with sickle cell 
anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a 
multicentre, open-label, phase 3, non-inferiority trial. Lancet, 387, 661-670. 
Ware, R.E., Eggleston, B., Redding-Lallinger, R., Wang, W.C., Smith-Whitley, K., 
Daeschner, C., Gee, B., Styles, L.A., Helms, R.W., Kinney, T.R. & Ohene-
 19 
Frempong, K. (2002) Predictors of fetal hemoglobin response in children with 
sickle cell anemia receiving hydroxyurea therapy. Blood, 99, 10-14. 
Yawn, B.P., Buchanan, G.R., Afenyi-Annan, A.N., Ballas, S.K., Hassell, K.L., James, A.H., 
Jordan, L., Lanzkron, S.M., Lottenberg, R., Savage, W.J., Tanabe, P.J., Ware, 
R.E., Murad, M.H., Goldsmith, J.C., Ortiz, E., Fulwood, R., Horton, A. & John-
Sowah, J. (2014) Management of sickle cell disease: summary of the 2014 
evidence-based report by expert panel members. JAMA, 312, 1033-1048. 
 
  
 20 
 
 Controls Hydroxyurea P value 
 n mean s.d. n mean s.d.  
age (years) 33 11.6 3.83 18 12.4 2.50 0.34 
Hb (g/l) 33 81.4 7.29 18 89.8 10.85 0.007 
MCV (fl) 33 83.2 7.43 18 94.3 13.70 0.004 
HbF (%) 33 6.7 4.14 18 15.3 8.02 <0.001 
HbF (g/l) 33 5.5 3.6 18 14.1 8.18 <0.001 
neutrophils 
(x109/l) 
33 5.0 1.50 18 3.8 1.81 0.017 
Reticulocytes 
(x109/l) 
33 389 92.2 18 227 89.1 <0.001 
bilirubin 33 42.7 16.3 18 38.9 19.4 0.46 
AST 33 59.8 24.5 18 51.7 21.9 0.25 
LDH 32 601 141 18 505 113 0.017 
 
Table 1: Comparison of laboratory and clinical measurements of those taking HC 
with those who were not. P values from t-tests, with significant results shown in bold 
(P<0.05). 
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Protein Number 
different 
peptides 
Normalized 
concentration 
in controls 
Normalized 
concentration 
on HU 
Fold 
change 
on HU 
P value 
Alpha-1B-
glycoprotein 
2 0.392 0.640 1.63 0.013 
Alpha-2-
macroglobulin 
71 0.895 1.17 1.31 0.003 
Apolipoprotein C-
III 
2 1.005 1.4 1.39 0.0039 
Fibronectin 17 0.729 0.968 1.33 0.00001 
Vitronectin 1 1.115 1.93 1.7 0.007 
Hemopexin 11 0.912 1.405 1.54 0.00098 
 
Table 2: Alphabetical list of all proteins with peptides at significantly increased 
concentrations (>1.3 fold) in children taking HC compared to controls. Where more 
than one peptide was increased from the same protein, the most significant 
difference is given. Concentrations are normalized against standard controls. 
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Protein Number 
different 
peptides 
Normalized 
concentration 
in controls 
Normalized 
concentration 
on HU 
Fold 
change 
on HU 
P value 
Alpha-1-acid 
glycoprotein 1 
2 0.619 0.412 0.66 0.001 
Carboxypeptidase 
B2 
1 0.702 0.526 0.75 0.012 
CD5 antigen-like 3 1.125 0.826 0.73 0.004 
Ceruloplasmin 40 1.23 0.873 0.71 0.001 
Coagulation 
factor XII 
1 0.887 0.676 0.76 0.011 
Complement 
component C9 
1 0.840 0.642 0.76 0.001 
Complement 
factor B 
1 1.43 1.015 0.71 0.014 
Cysteine-rich 
secretory protein 3 
1 0.594 0.451 0.76 0.0007 
Haptoglobin-
related protein 
1 2.21 1.385 0.63 0.007 
Hemoglobin 
subunit alpha 
95 2.065 1.28 0.62 0.002 
Hemoglobin 
subunit beta 
24 1.395 0.856 0.61 0.003 
Hemoglobin 
subunit delta 
2 2.42 1.35 0.56 0.0006 
Immunoglobulin 
mu chain C region 
1 1.87 1.38 0.74 0.04 
Immunoglobulin J 
chain 
1 1.095 0.801 0.73 0.02 
Platelet basic 
protein 
7 0.937 0.53 0.57 0.002 
Serotransferrin 9 1.47 1.085 0.74 0.002 
Vitamin D binding 
protein 
2 2.95 1.84 0.62 0.005 
 
Table 3: Alphabetical list of all peptides and proteins with concentrations decreased 
by a factor of more than 0.77 in children taking hydroxyurea compared to controls. 
Where more than one peptide was identified, the most significant difference is 
given. Concentrations are normalized against standard controls. 
 
 
 23 
 
 
 
 
 Hydroxyurea Controls P 
 N mean N mean  
PLXNB3 20 19.7 32 26.9 0.03 
IL-12 20 200 32 329 0.03 
LAIR-2 20 12.2 32 17.9 0.03 
 
Table 4: Concentrations of neurological biomarkers in children with sickle cell 
anemia, which were significantly different between patients on hydroxyurea and 
controls, after correction for multiple comparisons. Figures are based on normalized 
protein expression, assessing relative protein quantitation. PLXBN3 = plexin-B3, IL-12 
= interleukin 12 (measured as IL-12A and IL-12B subunits),  LAIR-2 = leukocyte-
associated immunoglobulin-like receptor 2. 
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 Pre-HC HbF% HbF% on HC HbF% change on HC 
n R P n R P n R P 
Alpha-1B-
glycoprotein 
14 .020 .945 21 .370 .099 14 .294 .308 
Alpha-2-
macroglobulin 
14 .271 .348 21 .288 .206 14 -.053 .858 
Apolipoprotein C-III 14 -.353 .216 21 .217 .346 14 .114 .698 
Fibronectin 14 .307 .285 21 .332 .142 14 -.102 .730 
Vitronectin 14 -.021 .944 21 .259 .257 14 .064 .829 
Hemopexin 14 -.208 .476 21 .533 .013* 14 .603 .023* 
Alpha-1-acid 
glycoprotein 1 
14 .153 .601 21 -.277 .224 14 -.471 .089 
Carboxypeptidase B2 14 .494 .073 21 .322 .155 14 .109 .710 
CD5 antigen-like 14 -.157 .592 21 -.296 .193 14 .151 .605 
Ceruloplasmin 14 .322 .262 21 -.406 .068 14 -.589 .027* 
Coagulation factor XII 14 -.437 .119 21 .122 .599 14 .187 .522 
Complement 
component C9 
14 .631 .015* 21 .375 .094 14 .341 .233 
Complement factor B 14 -.175 .549 21 -.017 .942 14 -.019 .948 
Cysteine-rich 
secretory protein 3 
14 .401 .155 21 -.366 .103 14 -.290 .315 
Haptoglobin-related 
protein 
14 -.315 .272 21 -.241 .292 14 .290 .315 
Hemoglobin subunit 
alpha 
14 .119 .685 21 -.514 .017* 14 -.412 .143 
Hemoglobin subunit 
beta 
14 .211 .470 21 -.515 .017* 14 -.382 .178 
Hemoglobin subunit 
delta 
14 -.016 .958 21 -.571 .007* 14 -.467 .092 
Immunoglobulin mu 
chain C region 
14 -.140 .634 21 -.250 .275 14 -.008 .978 
Immunoglobulin J 
chain 
14 .231 .427 21 .181 .431 14 .537 .048* 
Platelet basic protein 14 .210 .417 21 -.372 .097 14 -.581 .029* 
Serotransferrin 14 .184 .528 21 .095 .683 14 .312 .278 
Vitamin D binding 
protein 
14 -.065 .825 21 -.125 .589 14 .256 .377 
 
 
Table 5: Pearson correlation coefficients between plasma proteins (at the time of 
entry into the study)  and HbF percentage before starting hydroxycarbamide, when 
taking hydroxyurea (at time of entry into the study) and the increase in HbF 
percentage on hydroxycarbamide. 2-tailed P values are give and P values <0.05 
considered significant (marked with * and in bold). 
